Clinical Trials Browser

Breast Neoplasms × Vinorelbine × 1 year × Clear all

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Phase 2 Recruiting

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms, Recurrence

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Phase 3 Active not recruiting

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT07007559 2026-02-03

ASPEN-09

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3 Recruiting

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasms

NCT05063786 2025-09-08

ALPHABET

Phase 3 Active not recruiting

Breast Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 2 Active not recruiting

100 enrolled 15 charts

Breast Neoplasms

NCT03242616 2025-04-17

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

Phase 2 Active not recruiting

Breast Neoplasms